Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan

INTRODUCTION: Teneligliptin is a dipeptidyl peptidase 4 inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan in 2012. We performed a long-term post-marketing surveillance (RUBY) to obtain real-world evidence regarding the safety and efficacy of teneligliptin in J...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Takashi, Haneda, Masakazu, Ito, Hiroshi, Sasaki, Kazuyo, Matsukawa, Miyuki, Yamada, Yuka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089720/
https://www.ncbi.nlm.nih.gov/pubmed/31873865
http://dx.doi.org/10.1007/s12325-019-01189-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089720/
https://www.ncbi.nlm.nih.gov/pubmed/31873865
http://dx.doi.org/10.1007/s12325-019-01189-w

Ejemplares similares